secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-01-10T23:59:59+00:00
Accession:  0001140361-23-001223
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics transfers Nasdaq listing to Capital Market, effective Jan 11, 2023
--------------------------------------------------------------------------------

- Nasdaq Staff approved transfer from Global Market to Capital Market on Jan 9, 2023.
- Common stock begins trading on Capital Market at open on Jan 11, 2023 under symbol ERNA.
- Company voluntarily applied for transfer on Jan 2, 2023 (previously reported).
- Capital Market has similar corporate governance requirements but different financial listing standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123001223/0001140361-23-001223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123001223/brhc10046500_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-001223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer